---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004050"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:46:17.553761+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annexon prioritizes 4 flagship complement programs; GBS Phase 3 enrollment expanded to 220 patients

## Summary
- ANX005 Phase 3 in GBS expanded to 220 patients; pivotal data expected H1 2024.
- ANX005 Phase 2/3 pivotal in Huntington's to initiate in 2023.
- ANX007 Phase 2 in geographic atrophy on track for initial data mid-2023.
- Cash $269.5M as of Sep 30, 2022; operating runway updated to into 2025.
- Deprioritizing wAIHA; advancing ANX1502 (oral small molecule) into MAD study H1 2023.

## SEC filing metadata
- accession: 0001193125-23-004050
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312523004050/0001193125-23-004050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312523004050/d422908d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004050
- JSON: https://secwatch.observer/filing/0001193125-23-004050.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.